Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis

PURPOSE: Immunotherapy (IO) has significantly improved outcomes in metastatic renal cell carcinoma (mRCC). Preclinical evidence suggests that responses to IO may be potentiated via immunomodulatory effects of stereotactic radiation therapy (SRT). We hypothesized that clinical outcomes from the Natio...

Descripción completa

Detalles Bibliográficos
Autores principales: Piening, Alexander, Al-Hammadi, Noor, Dombrowski, John, Hamilton, Zachary, Teague, Ryan M., Swaminath, Anand, Shahi, Jeevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Scientific Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318269/
https://www.ncbi.nlm.nih.gov/pubmed/37408680
http://dx.doi.org/10.1016/j.adro.2023.101238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318269/
https://www.ncbi.nlm.nih.gov/pubmed/37408680
http://dx.doi.org/10.1016/j.adro.2023.101238

Ejemplares similares